Cite
HARVARD Citation
Sim, V. et al. (2019). The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience. Clinical oncology. 31 (7), pp. e114-. [Online].